title: Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.
abstract: High MET expression in renal cell carcinoma (RCC) and MET activation in bone metastases are reportedly important in progression of several cancers. To find new treatment targets in bone metastasis, we immunohistochemically analyzed expression levels of MET and matriptase (specific cellular activator of hepatocyte growth factor). We obtained nephrectomy specimens from 17 RCC patients with metastasis, and bone metastases specimens from 7 RCC patients who underwent metastasectomies, and who were treated at our hospital between 2008 and 2012. We tested the samples with anti-human MET polyclonal antibody and anti-human matriptase polyclonal antibody, and compared postoperative overall survival (OS) rates between positive and negative groups. High MET expression was seen at primary sites in 8/17 (47%) nephrectomy specimens, and 6/7 (86%) bone specimens. Matriptase was expressed in 6/17 (35%) nephrectomy specimens, and all 7 (100%) bone specimens. Interestingly, matriptase was strongly expressed in osteoclasts of 5/7 bone specimens. Postoperative OS rate was significantly higher in the MET(-) group than the MET(+) group. The high MET and matriptase expression seen in RCC cells in bone metastasis accompanied by matriptase expression in osteoclasts indicates their importance in bone metastasis.
authors.affiliation: Department of Urology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan, syoichiro_mukai@med.miyazaki-u.ac.jp.
authors.forename: Shoichiro
authors.initials: S
authors.lastname: Mukai
authors.forename: Kenji
authors.initials: K
authors.lastname: Yorita
authors.forename: Yukari
authors.initials: Y
authors.lastname: Kawagoe
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Katayama
authors.forename: Kozue
authors.initials: K
authors.lastname: Nakahara
authors.forename: Toyoharu
authors.initials: T
authors.lastname: Kamibeppu
authors.forename: Satoru
authors.initials: S
authors.lastname: Sugie
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Tukino
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kamoto
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kataoka
mesh_terms: D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000235:genetics* / Q000556:secondary*; D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000556:secondary*; D005260:Female; D015870:Gene Expression; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D007680:Kidney Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D019859:Proto-Oncogene Proteins c-met / Q000378:metabolism*; D012189:Retrospective Studies; D012697:Serine Endopeptidases / Q000378:metabolism*
chemical_list: C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met; D012697:Serine Endopeptidases; C485595:matriptase